Singapore markets open in 5 hours 16 minutes
Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.85 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
59,877.10 -2,106.23 (-3.40%) CMC Crypto 200
1,255.24 -79.68 (-5.97%)
PTCT Sep 2024 37.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:51AM EDT
Loading interactive chart…
- Zacks
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
- PR Newswire
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission (EC) for re-review.
- Zacks
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
© 2024 Yahoo. All rights reserved.